Efficacy, tolerability and pharmacokinetics of GS 9451 in patients with genotype 1a or 1b hepatitis C

Trial Profile

Efficacy, tolerability and pharmacokinetics of GS 9451 in patients with genotype 1a or 1b hepatitis C

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs Vedroprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2012 Primary endpoint 'Viral-load' has been met.
    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
    • 31 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top